Hello, everybody. This is Harald Hasselmann, the CEO of Eckert & Ziegler, speaking and inviting you for today's half year one results presentation of the year 2025. Starting with a typical disclaimer that is known to everybody, I don't have to read it. Now, this is a slide slightly adapted. Normally, you see the entire executive committee. The group of directors is now enlarged. We have a fully-fledged group executive committee. You know, the three upper persons here, Gunnar Mann, Frank Jäger, and myself. Let me put in the laser pointer here. These people, gentlemen, are known to you. Joe Hathcock is also part of the American business group, so does Ana Ramirez. We have in our group executive committee, five new colleagues joining them. Two people are representing the marketing and sales team. We have research and development by Dirk Becker. We have a specific person and colleague taking care of the Chinese business. Julian Schröder, you know him very well. He is taking care of all the topics which we are discussing here in terms of finance and controlling. He is well known. This is basically the enlarged business team running Eckert & Ziegler. I wanted to use the opportunity here to show all these faces to you that you know it's not only the one who's speaking to you today, together with Caroline, also participating in today's call, and Julian, but there's a big team. In front of that big team is here that group executive committee. Ladies and gentlemen, we are more than ever advancing really fantastic times. You see here a slide known to everybody with all the companies being active, being acquired or acquiring companies. That chart, I repeat in saying, becomes busier and busier every time I'm speaking here. Also here you see the customers we are supplying. To give you one example here, it was used to show a point. Now it's Eli Lilly or Eli Lilly Point Biopharma together because the acquisition, the concentration process of small companies being acquired by bigger companies continues, and that's to the benefit of all players. Here, some of those customers being published, either for lutetium on the left side, actinium, small amounts still, but important to have here a footprint. Then the CMO activities here. Ariceum is a new company joining our CMO/CDMO activities. We are happy that this chart from our customers gets busier and busier every time because that shows the importance of getting supplied with isotope produced by Eckert & Ziegler, either in the upper part for the medical segment here, what you are known to, and in the lower part for the industry segment, with all the calibration and validation services. What are the highlights of the last quarter? You are known that we are also showing what has happened in commercial practices and being worth to be mentioned here. There is Illuccix, that is a product of Telix, being approved in Germany. We are their distributor, we do expect that also in other countries, but in specific for Germany, that will enlarge the usage of diagnostic kits, not only from Novartis and other players in the market, but also now Telix joining that field. We are happy that there's another player, that will hopefully also induce more gallium-based imaging procedures. People coming together in Boston on a yearly basis. We do this in front of the International Oncology conference in Chicago every year, the ASCO, we do here our internal event together with more than 100 decision-makers from the entire field in radioligand therapy. We have a CDMO agreement with Pentixapharm, which was closed in April this year for the usage of Yttrium-90, Pentixapharm there, which is used for clinical trials. This is last year's data to start with. This is a jumping point, where we, where we ended last year with basically 50/50 in terms of revenue, Adjusted EBIT the number which we are going to report for quite some time, 56% by the medical segment and the remaining part by the industry area, IP here for the isotope business. 600 people here, 400 by the medical segment. This is the introduction part. I jump directly into the first half year and give you some data and overview. For those who have read already the press release, which Caroline published earlier today, there's always three lines to talk about. One is net sales, the other is Adjusted EBIT, the most important one because it demonstrate what really has been achieved on an operational perspective. Net income, what at the end of the day, after all extraordinary cost is left. We will come to each of the two business segments in a minute. In a nutshell, in spite of a lot of headwind, and circumstances which were unexpected in the first half year, I do repeat cyberattack and tariff and security and things like that, the sales have slightly been increased more in medical, less than Isotope Products area, but a slight increase in terms of net sales, currency adjusted, and that is also mentioned. It would have been better. We do see a weak dollar these days, in particular comparing that to last year. If we compare that with last year, the FX adjusted sales would be immediate single-digit growth that has been to a certain extent capped here due to the currency development. Adjusted EBIT, there is a strong growth which you see here, that is a good result because at the end EBIT is more important. You can only distribute what you have earned before. The EBIT margin goes up to 24%. Last year it was 22%. We see a lot of improvement in our profitability. Finally, if you look to net income and take away the Pentixapharm business or the comparison to Pentixapharm being part of last year's business in part, then it's almost 20% growth in net income. We have here a negative currency, financial and currency effect of EUR -0.6 compared to EUR 0.7 of last year, where we had a gain, currency gain, this year loss. On the other side, hyperinflation, Argentina became a little bit more feasible. Let's have a look to the two segments. As usual, I start with the medical segment. 15% growth in net sales. Basically what we do see is a continuous growth in the generator business, A, and B, for some time already, we are working in CDMO and CMO activities. This is when companies, pharma companies do approach us and say, "We have a kit, we have a tracer, we have a molecule, and we need to combine to label that with a radioisotope. Can we do this in your facilities?" We have a facility in Braunschweig, we have a facility in Berlin, we have it in Boston. We are using our facilities to offer these kinds of services for customers in very early stage, hoping, assuming that later on, when they go from clinical to commercial use, they will stay with us and continue to use our experience, knowledge and service. This business continues to grow. In addition to the generators sales, we have also positive development in the CDMO area. Another highlight is another license which we sold to an external partner in the amount of EUR 5 million for the actinium technology, and there's more to come in the second part of the year. Even a higher amount we do expect to come in in the second half. In terms of cost margin, strong growth, 41%. You see here the development and then also that induced a strong increase in the Adjusted EBIT margin to 29%, which is really extraordinary high. Happy to see that. The gross margin here, the gross profit, had an increase of almost EUR 9 million. If you go to the net income, there we see here the currency effect distorting the overall result and then interest in some restructuring of the IT infrastructure. Let's stick here to the upper two numbers, 15% growth in sales, 40% improvement in Adjusted EBIT. IP segment, the industry isotope segment is weaker. There we see -10% in sales and also Adjusted EBIT, a lower development in terms of the financial result. We have some distortions in here in terms of the product mix, which you see above. The oil well logging high profitable, high margin business unit was far below last year. We do expect a recovery during the outer part of the year. SPECT was better, but here we see a lower margin business and that gives you an impression that why the loss in sales is heavier in terms of Adjusted EBIT because of the unfavorable product mix, which we do see here, and that's why also the Adjusted EBIT margin went down from 23% down to 17%. Now, for those who are following us for a later period in time already, you might know that always the Adjusted EBIT margin in the IP segment used to be lower. This is the range we are used for. Last year was really extraordinary high in the first half-year. That's why it is sad, but it's not really a surprise because that brings us back to a range which we are normally used in that area. Still, we are very confident that in the remaining six months, the results will improve and then we will achieve what we have planned for. Looking to the upper part of that slide, you see that it is not a 50%/50% game anymore. The medical segment is stronger in terms of overall growth. It's more than 50% in here. Isotope Products is 46%. Not a surprise. Anticipated, wanted, and forecasted, but it's even still growth we are to demonstrate. For those who want to have a bridge from the EBIT reported to the one which is Adjusted EBIT, there might be more questions coming up later on. I will not so much talk about medical, isotope or others. Let's have a look to the overall result. EBIT reported EUR 33 million. Overall result, EUR 35. Most of that is coming from the IT restructuring out of the cyberattack and here currency effect, as I mentioned early on. These are the two main effects which were influencing here the difference from EBIT reported to Adjusted EBIT. Revenue growth, split across the countries. We see a growth in Europe, 7%. Unsecurity in North America during the first half year. That's why what I presented earlier on, where is the shortfall coming from? It's coming from North America, which is now representing 46% overall. Asia strong, Asia grows, but that has also a lot of reasoning in the license which we gained here, EUR 5 million in the first quarter of this year. That's why we have a strong jump here of 31% compared to last year due to that license agreement which we did. That also influences that Asia now represents here 16%, slightly higher than anticipated, but due to the license effect I just talked about. Core business, ladies and gentlemen, is still radiopharmaceutical, and here we see a continuous growth. Last year 10%. If we do what controllers like to do, take first half year's number and do an extrapolation, then EUR 140 million or whatever is the number we do anticipate out of extrapolation. That would be 10% growth compared to last year. Our guidance is based on EUR 150 million. You see here still a difference between ex- controlling extrapolation and our guidance. Reason is easy to explain. That is why more licenses will come in the remaining part of the year, that will then jump from the extrapolation number to the guidance number, which we do confirm here once again. The mixture of these radiopharmaceutical products are mentioned here. It's pure isotopes, it's isotopes in a generator, it's cold kits, it's the CDMO and CMO activities I talked about, and it's all kind of radiopharmaceutical production equipment composing that sales growth. Looking to the quarters, softer quarter in the beginning of the year. Reasons were given when I talked to you last time due to the cyberattack and others. A recovery in particular in the generator business in Q1, and that's why you see here the 90% growth for the radiopharmaceutical business. These numbers are hopefully known to you or you are used to these ranges where we have that growth over the year. Let's have a look to the balance sheet. The balance sheet, there are lots of items you might be interested in. I'd like to point in here EUR 100 million, more than EUR 100 million for cash because we have a positive cash development. Low numbers in loan liabilities. The rest is relatively stable. A balance number of EUR 439 million is what we have shown also last year. Here you see a number of 52%. I think the number is going down to 51%. This is rounded numbers, okay. Here you see 51.5%, the other was 52%. That depends from which. The beauty is eye in the beholder; it's in the same range than last time. It's a little bit lower than the year before, that is just because Pentixapharm was responsible for having a long balance sheet, that is now out of the license. You see here the liabilities go down, cash goes up because strong cash flow from operative, that is accumulated, that's why we have here that number. Payments is the same. Adjusted EBIT, we talked about that strong increase of 9%. Here again, some key figures to summarize the numbers. Revenue, cash flow higher than last year, EBIT higher than last year, balance and the securities improvement and equity ratio more or less the same due to the reason I given. Last slide from my side before we jump into the Q&A session. That is we stick to the guidance which we have published at the beginning of this year with a sales number of around about EUR 320 million within the normal corridor and an Adjusted EBIT of EUR 78 million, same assumption and conditions as I just made. We do confirm here both guided numbers and are confident to fulfill our mission to be a supplier of choice and hopefully also an investment for all the shareholders. Thank you very much. With this one I close the official presentation for commercial numbers and giving here just an outlook where we can see each other again and hope we will have a lot of questions. There is Alexander Galitsa. I think he dialed in yesterday, ready to be number one. Alex, you have here first in row. Please go ahead. A couple of topics, quite a few actually. What's the best way? Maybe to start off, just to have it done, IP Segment. This - 10% top line in H1, I think - 6%, without currency effects, quite a dip considering you still expect growth for the full year. Just wondering if you could talk to your visibility, how you planning to achieve acceleration to such an extent in the second half of the year. I think you require around 20% top line growth in the second half, to reach the EUR 155 million I think you outlined for the full year. Basically, what gives you confidence and whether there could be, I think you're mentioning project related, delays, whether this can be something that will ultimately end up pushing revenues into 2026. That's for the IP, and then maybe medical, we'll do afterwards. Very good. Yeah. The number of EUR 155 million is the number which had been published. There are lots of reasons. At the end of the day, we are confirming that number. We are doing all in our hands to achieve that. Now, to give you a small example, is tariffs between U.S. and China. When the whole discussion started how to deal with the tariffs, the Chinese importers were hesitating in placing orders. Now, at least as of today, 3:20 P.M., there is not a complete relief, but the countries and governments are talking to each other again, i.e. we see a recovering pattern from our importers, from our Chinese importers to start ordering again. That is also for the case for European importers being hesitating by saying, "Oh, can we still import from this? What is Europe doing?" Things like that. There was a lot of reluctancy in saying, "What do we do? What can we do? What do we want to do?" in the first years. What we have now recognized that not completely, but people are going back to a more normalized purchasing pattern. That's why we see here an improvement already started and that is going to be continued. In terms of businesses which we were lacking in the beginning, one of this I mentioned already, that is oil well logging. There we were lagging orders, but we know that this will come in a seasonal approach, and whatever did not come in in the first half year is supposed to come in the remaining part of the year. That is the second reason. The third one is projects you mentioned. We do not have specific income projects. We have a lot of construction sites or investment projects in South America, for instance, where we erect a new facility in São Paulo in order to have more production capacity, but that was not planned to generate additional sales already in this year. This is the overall perspective for IP, and if Julian doesn't take out the hammer and say something different, then these are the numbers which we are going to confirm. You have also some questions for medical? Yes. On the medical side, I see that Q2 and H1 is sort of on the underlying basis, stripping out the licenses from the joint venture is on the lighter side in terms of growth. I think for the medical division, first half is 8%, for the Radiopharma, it's around 10% H1. The same question here, I think you need an acceleration in the second half of the year to reach the targets. Again, I think if you could add any context to in what verticals do you expect to see more dynamic versus the first half? Maybe in this context also, if you could explore on whether some of the newer growth areas are contributing more now. I think you were mentioning CMO, CDMO, if that's meaningful already, and also maybe with regards to actinium, lutetium, how those isotopes are performing and is that already at the magnitude that is meaningful for the group? Absolutely. Good question. Yeah. In introducing statement is A, we are focusing on license deals, and these license deals will stay as one income opportunity, revenue opportunity for last year, this year, and the years to come. With license deals, it's always, it's not a linear curve. If you have a license deal in a specific quarter, then later on you compare that data with that quarter with next year's quarter, there might be some distortions. The same is here. We have had a license deal last year, quite substantially. We have a smaller amount at the beginning of this year. Now the next license income is only planned for Q4. That was published and mentioned earlier on. It is a curve which goes that. It's flat, then you have an income, then it's flat again, and then you have a stronger income again, and then it's flat again. If you want to compare apple to apple to apple to apple, you might take out the license income. I would not recommend to do so because this is not extraordinary income, it's ordinary income, but it does not go in a linear income. That's why if you take first half year's number and multiplying with two, you will not reach what I want to reach by the end of the year. That's why the license deals which are supposed to come out of the existing contracts have to be added on that. A. B, is the actinium activities. The performance of pure actinium sales is still less than EUR 1 million as of today. It is still low because the numbers which are required, the demand is extremely strong, but what we are really selling as a purified isotope is very, very small. That will change only by next year. I do not expect a stronger increase for actinium, for the pure actinium sales by this year. Lutetium is a different story. Lutetium, we see after getting here the approval and all the licenses and all the certificate which were needed, that there is more to come, and we are currently exploring also different opportunities. That is not only the case for the deal with Eli Lilly and Point, but also other customers are asking for additional income and supply here. CMO, CDMO, right. We have an existing site in Braunschweig doing CDMO's activities, I would say for more than five years. In Berlin, we are doing it for one year, and in Boston, we started this year. There is a different uptake curve, and Braunschweig is developing well and profitable. Berlin is developing well and break even, and Boston is still to come. These are three different types in which we are active, and I do expect that by the remaining part of the year, there will be stronger performance as of the for the as we have seen it for the first half year, and that is going to be continued by next year. Overall, here, again, I also do confirm that the guidance is within what we wanted to achieve. Thank you. Just two follow-ups, then I go back in the queue. On lutetium you mentioned other customers that have inquiries. Would that be for clinical usage, or is there also commercial opportunities here? No, that is also for commercial usage. These are individual customers like hospitals or clinics which are asking to be supplied with our products. Okay ... pharmaceutical companies, we are in preparation of specific deals, and that bill is still under negotiation. I'm pretty sure that there is more to come. We can hopefully also publish, being allowed to publish, being signed anyway in terms of doing CDMO work for pharma companies. The last follow-up is on the licensing. Are you currently working on any other potential licenses for, I guess technology transfer beyond the ones that you have signed with Telix and the joint venture? Is that currently not in the scope of, the, I guess, activities? Yeah. Yes, and how you take. We are talking to pharma companies how to best serve their needs and how to best match their interest. That can be either in a pure supply contract or it can be combined also with some kind of technology transfer. That could also happen to other parties as well. If, if you'd ask me now, is there something which will happen by tomorrow? I would say there's nothing happen by tomorrow. Will there be something during the rest of the year? Could be. Depends also. There's nothing concrete where I say, "Don't sleep because there will be a press release by tomorrow." We are working on that because I mentioned licensing is part also of our business. Thank you. Okay. Super. PN. Hey, Harald. Thanks for the presentation. Maybe a few question on my side. If we stick on what you are just saying about the lutetium revenues, would be interesting to see how much of, let's say, the target that you gave a few years ago on doubling the medical segment revenues by 2028, how much of that will be tied to the Point Biopharma agreement that you have? Because we're starting to see maybe some delays when it comes to Lilly and Lantheus on that. It would be interesting to see what's the exposure and is there any risk from delays happening on that? Mm-hmm. Mm-hmm. Okay. Okay. I'll follow up with a second one, which will also be on the medical segment and the gallium generators demand. Do you see any impact from the positive news load that Novartis had and the new indication launch that they had to expand the patient pool? Do you see more customer coming on and knocking on the door? Do you think that there is some threshold in term of number of patient that you need to have to double the number of generators in one hospital, and that might take, I don't know, a new indication and new population rise to happen? Mm-hmm. Then I will have other questions, so I guess after these two. Okay. Okay. Okay. Yes, the lutetium outcome for Point with their product was not as promising as they wanted to have it, that is public knowledge. Nevertheless, the triangle between Lantheus, Point, and Eli Lilly is reconfirming our cooperation agreement, i.e. to deliver what they want. Yes, there's a slight delay in kicking off or the hockey stick in terms of their demand is to a certain extent moved to the right, not left, but to the right direction, in terms of getting that data. That's true, but on the other side, we see also that other companies have an interest in taking our lutetium for validation samples. If you do a validation sample, that is then hopefully followed also by a supply contract. We are working on compensating that delay for one customer by getting more customers. The medical generator business, it's a double-Blind question. A is, yes, the Novartis result is very positive, and that will for sure lead to more Pluvicto or PSMA -617 treatments. In order to do so, you need more imaging procedures before that. Split it, however, into gallium and fluor. And that is also then FDG on the one side and gallium-based kits on the other side. That's why we have to always say the growth is to the benefit of the two suppliers. We have not seen yet that all of a sudden, the demand of generators is exploding. We do see is that the replacement of a generator goes faster, or with other words, that the demand for a higher activity generator, i.e. the gallium 100, stays unbroken. That's why we have increased our purchasing activities for germanium. We are producing more GalliaPharm 100, and that leads also that the average price for a generator, if you put everything together and divide it with the number of units you are selling, is increasing despite negative currency effect or despite whatever competition, despite whatever. We see an increase in the average price because of more GalliaPharm 100 positively influencing that way. Second answer is, we do expect still in this quarter the approval for Novartis in China and Japan, and we are together with this company in these two areas. It is followed by reimbursement discussions. To get the market authorization for GalliaPharm in China and later on also for GalliaPharm in Japan is a severe and important milestone to also entering that territories. Will that lead immediately to a strong increase in sales? No. Will this enable us to have more business opportunities? Yes. Okay. Super clear. Mm-hmm. Maybe just a very yes or no probably answer, on the generators, is it fair to assume that the higher dosage are more profitable for you, or it's the same thing? That is correct. Okay, great. Maybe one last question, and then I will go back in the queue. Just on the let's say big picture side, do you get some let's say more cautious view from potential customer that are delaying the launch of the clinical studies or from, I don't know, a new company that wanted to buy some of your equipment for the maker segment? Does the macro has impacted the activity, or you don't really see anything on that front? In terms of what? Hot cells, for instance. Something like that. The order book for this year is full. The order book for next year is almost complete, not fully. Do we see a certain degree of satisfaction? Not yet, the question is to what extent hot cells providers like our business, but also from our competitors, are also entering new fields. That is the question which we are currently investigating also to go into a broader area of scope in providing hot cells in order to compensate something like a certain satisfaction which might come. We should not forget that other areas have completely not really made any big business approach, South America or Asia. We are not really active so much in these territories yet because we were fully busy, but that would be then the next step. Okay, super clear. I will go back in the queue then. Thanks. As I only see here the two capital letters. I don't know who asked this. I don't see. Hello. This is Alexander Galitsa. Hello, Dr. Hasselmann. Could I ask a question on Telix new product, Gozellix? Do you expect this to be a net positive or negative outcome? Okay. That will be a high activity kit, which they are trying to get that being produced in cyclotron base. That will enable a broader acceptance of gallium-based kits, which is a good development because everything which helps to demonstrate the quality and the effectiveness of gallium is to the benefit of all gallium providers, be it generator or cyclotron produced. It's good news. Will it harm the business of the gallium business itself? I don't see that happening because it is a cyclotron in those centers where you anyway have a center, and then it's rather a competition between gallium produced on a cyclotron versus FDG produced on a cyclotron. That is rather the competition takes place in these big, centered hospital, and not so much of the overall field radiopharmacies. Will there be one hospital which is saying, "Okay, instead of buying one generator, I only buy half of generator?" Yeah, that could happen. Okay. Thank you. I'll be quick. I only have a couple more questions. The U.S. revenue's down 8%. Could you, could you explain what was behind that? I don't think the foreign exchange could have had that much of an effect. Was that some particular effect in medical? Yeah. I mean, That is one area. First of all, we had a weak start in this year. I must confess it, due to the cyberattack, and then we have other topics. I also mentioned the tariff topic, which was really difficult to and induce a lot of hesitation for potential customers. And then the oil well logging business was really weak in the beginning of that year and there we are confident that this will be recovered. Basically, it was mentioned already, and we saw that development in Q1 already coming up, and that has been now demonstrated. As we are talking about figures up to June, it is as I mentioned, if I had to include July figures here, then we would see that the improvement continues and that will go. Right, you are we happy with the result of Q1 and the first months of Q2? No. Are we confident that this will change in the outer part? Yes. Thank you. My penultimate question is, just to check, license sales are excluded from the definition of radiopharmaceuticals. Is that correct? Is any portion of them recurring or is it a one-off technology transfer, as we would think of a purchase and a sale like that? Okay. Yeah. That depends from license deal to license deal. The second one, which we entered in this year, is also linked to royalties. Mm-hmm. The other one, which was published last year. That is a higher amount with no royalties. The other one is a lower upfront payment, but with royalties. Okay. Okay. That's very clear. My last question was, are you planning to come to the Jefferies conference in London in November? Yes. Excellent. Thank you. Okay. We'll make the meeting. Thank you very much. Thank you so much. Sorry, I have to jump in for a second. Yeah. The question was whether the license deals are included in radiopharmaceutical sales, correct? Yes, that's correct, Julian. Yes, sorry. They are included. I have to correct Harald, unfortunately. Thank you very much, Julian. No, no. That was his stay for Julian here. Julian, thanks for joining. Welcome. Super. Thank you. Good. Who's next? Is it off? I think that is Alexander again. Alexander. We start again. Super. Yes. Thanks for additional follow-up. Just maybe to clarify on Lantheus to Eli Lilly point, I was a little bit surprised hearing that this is somewhat of a still potential for you. I think Lantheus publicly have dropped the engagement, and I think Eli Lilly has also deprioritized the asset. I'm just wondering, like, what's the dynamics? Is it something still that you hold as of relevance for- Yeah. The next. That is easy said. Eli Lilly wants to enter the field of RT and radioligand therapy. Statement one. Second statement, they have inherited a supply contract and we went through that supply contract, and they are very committed in continuing exploring their business opportunities in the field of lutetium-based treatments. There is not only one agent which they indirectly, via the cooperation with Lantheus, have hand on in terms of marketing and sales. They have more than one compounds, that's why they are saying, Okay, that is off, but this is to come, and this is what we enter. Then they want to have more, that's why the statement which we receive is very clear, no reason to deviate from the overall supply contract. As mentioned earlier, there's a soft shift to in terms of timing, but no deviation from the overall commitment. Okay. On the yttrium, I think you mentioned in the presentation somewhere that APAC expansion ongoing. Could you maybe add more context to that? I think Sirtex was always having this untapped potential in China for many years. They had difficulties in really penetrating the market. Is that something? Has something changed there? Do you see more dynamic or what caused you to put it that way, that there is the expansion ongoing in the APAC? No. Maybe it's not related to China. No, no. More context would be helpful. The increase in APAC was a license deal, which we have had with Actinium, and that is shown under China. I was referring specifically to the chart. Yeah. ... where you show all the isotopes and under yttrium, there is a bullet point which says, "APAC expansion ongoing. Yeah. ... wondering whether APAC expansion means relates to China or maybe other markets, and if it's? No. Then. Yeah. Let me check here. Where is it? Where was it? On which slide do you have it? Let's see here. It's chart number, slide number five. Five. The second bullet point. Yeah. APAC expansion. Yeah. Ongoing. Yeah, yeah. Right you are. Right you are. That is just the case that we are producing Yttrium-90, A, for Europe, and B for the U.S., and in GMP quality for China, and that their demand is growing. If you recall what I said two years ago, and you quote me correctly, then I said, by that time, probably in five years' time, China should be as big as rest of the world. That is not happening because the penetration into the Chinese market from SIR-Spheres precisely is going much slower than anticipated due to whatever their bus. Are we getting more stuff into the Chinese market? Yes. Are we preparing to increase the production numbers? Yes. Is it as fast and as big as we want to, have it? Not yet. Okay. So- Understood. Last question. It's, perhaps, it's a little bit then exaggerating, your comment. Is it expanding? Yes. Continuing to expand into that market would be the right wording. Last question is related to lutetium. Just wondering whether you have given up on hopes to be supplying? No. No. At some point. No With lutetium? No. No. No. Okay. We are trying it to approach it from a different angle now. Can we be as a pure stupid supplier, this all honorable approach, or can we combine it with the services, i.e., CDMO work? That is something which we are exploring, and that might give us, not immediately, but that gives us the good hope, reason for good hope there also to enter into that field by bypassing a normal ordinary supply contract, but doing here also some CDMO work, and then later on become there. That would be for a different asset, not the one that they have already. Not, not for prostate. Okay. For the prostate, you have given up? Okay. Do I give it up? No. Is it realistic that I make an announcement tomorrow? No. Understood. Okay. Thank you. Any other question, comment, wish, desire? That is not the case. I thank you very much for your attention. Thanks to everybody, and speak to you soon again. Have a good day and a good weekend. Bye-bye.